Public Law No. 119-21, the One Big Beautiful Bill Act (OBBBA), represents the most comprehensive overhaul of the federal tax system since the Tax Cuts and Jobs Act of 2017 (TCJA). Enacted on July 4, 2025...
Restaurant leasing presents a unique blend of legal considerations, shaped by operational realities such as equipment needs, utility demands, and customer-facing enhancements. Review this checklist for...
In today’s deal-making space, environmental liabilities can be hidden landmines threatening post-closing value and operational integrity. Navigate the intricate terrain of M&A transactions where...
This practice note helps attorneys representing drug and medical device manufacturers advise their clients about liability risks associated with their products, by summarizing the legal landscape surrounding...
Do you want to stay up to date on recent developments and guidance regarding gun safety in the workplace? Watch our new Current Awareness: New Developments in Gun Safety Legislation Video , by Alka Ramchandani...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
The most robust due diligence disclosures are keyed to the company’s industry, stage of growth, and other particular circumstances. Pharmaceutical companies operate in a highly-regulated space, while development-stage companies in that industry face high costs of entry and often a lack of familiarity with the details of the approval process for their products. Use this template as a basis for getting the information you need from management to make all appropriate disclosures in the offering documents.
READ NOW »
Related Content
Practical Guidance Updates Featuring the latest updates from your Practical Guidance account.
PRACTICAL GUIDANCE CUSTOMER EMAIL EDITION ON THE WEB
Experience results today with practical guidance, legal research, and data-driven insights—all in one place.Experience Lexis+